AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.032

-0.001-3.03%

Volume:24.95M

Turnover:785.01K

Market Cap:47.16M

PE:-0.59

High:0.034

Open:0.034

Low:0.030

Close:0.033

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:2.52

T/O Rate:2.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.054

ROE:-77.31%

ROA:-42.45%

PB:0.77

PE(LYR):-0.59

Loading ...

Overview Company News Filings

Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc

THOMSON REUTERS

Immutep - Tacti-4 Root Cause Analysis Ongoing, Results Expected Q3 Cy2026

THOMSON REUTERS

Immutep - no New Safety Signals Observed to Date in Tacti-4

THOMSON REUTERS

Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial

MT Newswires Live

ASX Penny Stocks: Immutep And Two More Companies To Watch

Simply Wall St.

Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation

Simply Wall St.

Immutep Raised to Buy From Hold by Maxim Group

Immutep Ltd : Maxim Group Raises to Buy From Hold

THOMSON REUTERS

Immutep Says JPMorgan Ceases to Be Substantial Holder

MT Newswires Live

Immutep Says First-in-Human Study Assessing Autoimmune Disease Drug Candidate Meets Primary Endpoint; Shares Down 4%

MT Newswires Live

Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026

Immutep - Efti + Soc Shows Median Overall Survival Improvement of 7.7 Months in Alc Responders

THOMSON REUTERS

Immutep - Announces Results From 5 Clinical Trials of Eftilagimod Alfa in Late-Stage Cancer

THOMSON REUTERS

Immutep Reports Survival Benefit Linked to Immune Response in Efti Clinical Trial Analysis

MT Newswires Live

Immutep says eftilagimod alfa plus standard care boosts overall survival in late-stage cancer study analysis

Immutep executives face securities class action after ADRs plunge 83% on trial collapse

Immutep Receives Nasdaq Notice of Bid Price Deficiency

THOMSON REUTERS

Immutep gets Nasdaq notice for breaching US$1 minimum bid price rule

BRIEF-Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance

Immutep Ltd - Receives Nasdaq Notice of Minimum Bid Price Non-Compliance

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/IMM.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.032,"timestamp":1790921520000,"preClose":0.033,"halted":0,"volume":24951559,"delay":0,"changeRate":-0.030303030303030328,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"Closed","change":-0.001,"latestTime":"10-02 16:12:00 AEST","open":0.034,"high":0.034,"low":0.03,"amount":785008,"amplitude":0.121212,"askPrice":0.032,"askSize":1097305,"bidPrice":0.03,"bidSize":2010466,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791154800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.033,"openAndCloseTimeList":[[1790899200000,1790920800000]],"volumeRatio":2.523883,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.033,"auctionPrice":0.031,"auctionVolume":1821066,"auctionTime":1790921400253,"referencePrice":0.032,"referenceTime":1790937003087,"auction":3,"marketStatus":"盘后竞价","timestamp":1790921400253}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":2.523883,"shares":1473721306,"dividePrice":0,"high":0.034,"amplitude":0.121212,"preClose":0.033,"low":0.03,"week52Low":0.028,"pbRate":"0.77","psRate":"2.37","week52High":0.47,"institutionHeld":0,"latestPrice":0.032,"committee":0.293831,"eps":-0.0539,"divideRate":0,"volume":24951559,"delay":0,"ttmEps":-0.0539,"open":0.034,"prevYearClose":0.415,"prevWeekClose":0.036,"prevMonthClose":0.034,"prevQuarterClose":0.034,"fiveDayClose":0.036,"twentyDayClose":0.048,"sixtyDayClose":0.051,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651196131","title":"Immutep - Insight-3 Shows Mature Median Overall Survival of 30.9 Months in 1L Non-squamous Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651196131?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119690","title":"Immutep - Tacti-4 Root Cause Analysis Ongoing, Results Expected Q3 Cy2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119690","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119690?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651119615","title":"Immutep - no New Safety Signals Observed to Date in Tacti-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2651119615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651119615?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:00","pubTimestamp":1783944003,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nTUA2HW17Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651819633","title":"Immutep Says Median Overall Survival 30.9 Months for Non-Small Cell Lung Cancer Patients in Phase One Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2651819633","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651819633?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:36","pubTimestamp":1783924582,"startTime":"0","endTime":"0","summary":"Immutep  said the median overall patient survival was 30.9 months in patients in its INSIGHT-003 phase one trial, evaluating eftilagimod alfa, or efti, in combination with Merck's anti-PD-1 therapy Keytruda, or pembrolizumab, and chemotherapy as first-line therapy for advanced or metastatic non-small cell lung cancer in 51 evaluable non-squamous patients, according to a Monday Australian bourse filing.Around 92% of patients enrolled in the trial had no or low programmed death-ligand 1  expression, with a tumor proportion score under 50%. The median overall survival was 37.8 months in patients with a tumor proportion score of over 50%.The results compare favorably with historical benchmarks, the filing said.Preliminary immune monitoring data generated from its discontinued TACTI-004 phase three trial indicated that patients treated with efti showed a different immune activation profile compared with those observed in previous studies. The TACTI-004 analysis is ongoing, with additional r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645856336","title":"ASX Penny Stocks: Immutep And Two More Companies To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2645856336","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645856336?lang=en_us&edition=fundamental","pubTime":"2026-06-24 03:02","pubTimestamp":1782241379,"startTime":"0","endTime":"0","summary":"The Australian market is poised for a 20-point advance at open, reflecting global optimism despite recent tech sector jitters overseas. While the term 'penny stocks' might seem outdated, these smaller or newer companies still hold significant potential when supported by strong financials. In this article, we explore three promising penny stocks that combine balance sheet strength with growth opportunities, offering investors a chance to uncover hidden value in quality companies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-oec/orbital-shares/news/asx-penny-stocks-immutep-and-two-more-companies-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-oec/orbital-shares/news/asx-penny-stocks-immutep-and-two-more-companies-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7104","TCG.AU","BK7067","BK7506","BK7115","BK7508","IMM.AU","OEC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644061818","title":"Here's Why We're Watching Immutep's (ASX:IMM) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2644061818","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644061818?lang=en_us&edition=fundamental","pubTime":"2026-06-20 04:03","pubTimestamp":1781899385,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/heres-why-were-watching-immuteps-asximm-cash-burn-situation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-imm/immutep-shares/news/heres-why-were-watching-immuteps-asximm-cash-burn-situation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644744422","title":"Immutep Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2644744422","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644744422?lang=en_us&edition=fundamental","pubTime":"2026-06-17 22:23","pubTimestamp":1781706180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMMP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 10:23 ET (14:23 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK7067","IMMP","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644745390","title":"Immutep Ltd : Maxim Group Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745390?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:56","pubTimestamp":1781697414,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42P0DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","IMMP","BK7067","BK4139","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642417302","title":"Immutep Says JPMorgan Ceases to Be Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=2642417302","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642417302?lang=en_us&edition=fundamental","pubTime":"2026-06-10 12:53","pubTimestamp":1781067196,"startTime":"0","endTime":"0","summary":"Immutep  said JPMorgan Chase & Co. and its affiliates ceased to be substantial holders of the company on June 5, according to a Wednesday Australian bourse filing.JPMorgan Chase & Co. and its affiliates became substantial holders on June 3 with a 5.2% voting power, an earlier filing showed.Immutep's shares were down past 2% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2505996509.AUD","LU2552382215.SGD","LU0820561909.HKD","LU2106854487.HKD","LU0211326755.USD","LU1116320737.USD","LU2023250504.SGD","LU1084165304.USD","LU1670628061.USD","BK4504","BK4534","IE00BJLML261.HKD","LU0820561818.USD","JPM","BK4516","LU0345770308.USD","LU2746668974.SGD","IE00B3S45H60.SGD","IE00BN8TJ469.HKD","LU0106261372.USD","LU1894683264.USD","LU2462157665.USD","LU2023250843.SGD","LU1162221912.USD","BK4585","BK7067","LU0787776722.HKD","LU1366192091.USD","JPO","LU0868494708.USD","PGF","LU2237443465.HKD","LU1064131342.USD","IE00BJTD4V19.USD","JPX","IMM.AU","JPMO","LU0211331839.USD","LU2054465674.USD","IE0034235295.USD","BK4588","IE00BDRTCR15.USD","LU0496365809.HKD","LU2430703251.USD","IE00BLSP4452.SGD","LU0211326839.USD","SG9999002224.SGD","IE0034235303.USD","IE00BLSP4239.USD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640298135","title":"Immutep Says First-in-Human Study Assessing Autoimmune Disease Drug Candidate Meets Primary Endpoint; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640298135","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640298135?lang=en_us&edition=fundamental","pubTime":"2026-06-04 10:06","pubTimestamp":1780538771,"startTime":"0","endTime":"0","summary":"Immutep  said a first-in-human phase one study evaluating IMP761, a potential therapeutic option for autoimmune diseases, met its primary endpoint, showing favorable safety and tolerability in healthy volunteers in the single ascending dose part of the study, according to a Thursday filing with the Australian bourse.IMP761 was designed to target activated T cells at inflammation sites to reduce pathological immune responses while preserving systemic immune function, the filing said.Early findings showed \"significant and clinically relevant\" pharmacodynamic activity, including the reduction of local inflammatory responses and attenuated T-cell activity compared with placebo across groups ranging from 0.9 milligrams per kilogram to 7 milligrams per kilogram, per the filing.Shares fell nearly 4% in morning trade Thursday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640737180","title":"Immutep reports positive interim Phase I data for autoimmune drug candidate IMP761 at EULAR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640737180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640737180?lang=en_us&edition=fundamental","pubTime":"2026-06-04 08:11","pubTimestamp":1780531906,"startTime":"0","endTime":"0","summary":"Immutep flagged positive interim Phase I data for autoimmune candidate IMP761, with results set for presentation at EULAR 2026 on June 4.The first-in-human trial in healthy volunteers met its primary goal, showing favorable safety and tolerability.Early readouts showed pharmacodynamic activity consistent with immunosuppressive effects versus placebo, supporting further development in autoimmune disease.The pharmacokinetic profile supports dosing about once every four weeks, shaping the program’s Phase II planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL3NVp6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698766","title":"Immutep - Efti + Soc Shows Median Overall Survival Improvement of 7.7 Months in Alc Responders","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698766?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:10","pubTimestamp":1779970241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250NC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698713","title":"Immutep - Announces Results From 5 Clinical Trials of Eftilagimod Alfa in Late-Stage Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698713?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:10","pubTimestamp":1779970241,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638365224","title":"Immutep Reports Survival Benefit Linked to Immune Response in Efti Clinical Trial Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2638365224","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638365224?lang=en_us&edition=fundamental","pubTime":"2026-05-28 13:56","pubTimestamp":1779947778,"startTime":"0","endTime":"0","summary":"Immutep  said a systematic evaluation of five clinical trials of eftilagimod alfa , an antigen-presenting cell  activator, in combination with standard-of-care therapies in late-stage cancer patients showed a significant increase in circulating absolute lymphocyte count  compared to standard-of-care alone, according to a Thursday Australian bourse filing.The company said increased ALC was significantly associated with improved clinical outcomes, with ALC responders in the efti plus standard-of-care group showing a clinically meaningful median overall survival improvement of 7.7 months compared to ALC non-responders, with no corresponding association observed in the standard-of-care alone group.\"The findings link the immune-activating effect of efti measured in patients' blood with meaningful and significant survival improvements observed in previous clinical trials,\" said Immutep's Chief Scientific Officer, Frederic Triebel, adding that the studies highlighted a key connection with eft","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1674673428.USD","BK7094","LU0149725797.USD","LU1496350171.SGD","ALC.AU","LU1778281490.HKD","LU0314104364.USD","LU2083900584.USD","BK7095","LU1935042215.USD","LU1935042488.USD","LU0786609619.USD","BK7067","LU2236285917.USD","BK4214","BK7508","LU2237443978.SGD","ALC","LU2456880835.USD","LU1718418525.SGD","LU0053666078.USD","BK4534","LU1935043023.USD","LU2237443549.SGD","LU1066051811.HKD","LU1066051225.USD","LU1804176565.USD","LU0882574139.USD","LU2237443622.USD","LU2417539215.USD","LU0170899867.USD","IMM.AU","LU1066053197.SGD","LU2237443382.USD","LU1935042991.SGD","APC","LU2420271590.USD","LU0157215616.USD","LU1366333091.USD","LU2265009873.SGD","APC.AU","LU0077335932.USD","LU1935043536.SGD","BK4198","LU1674673691.USD","LU1366192091.USD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638658881","title":"Immutep says eftilagimod alfa plus standard care boosts overall survival in late-stage cancer study analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2638658881","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638658881?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:04","pubTimestamp":1779930262,"startTime":"0","endTime":"0","summary":"Immutep disclosed a pooled evaluation of five eftilagimod alfa combination trials in late-stage cancers, linking immune activation to better survival outcomes.Patients showing a treatment-related immune response tended to live longer than non-responders, a pattern not seen with standard therapy alone.Findings were consistent across multiple tumor types and across combinations with chemotherapy or PD-1-based immunotherapy.The analysis excluded the discontinued TACTI-004 Phase III lung cancer trial, limiting read-through to earlier-stage studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL9l2P64:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333915","title":"Immutep executives face securities class action after ADRs plunge 83% on trial collapse","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333915","media":"Reuters","labels":["executive","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333915?lang=en_us&edition=fundamental","pubTime":"2026-05-21 21:08","pubTimestamp":1779368914,"startTime":"0","endTime":"0","summary":"Immutep faces a securities class action tied to investor purchases from March 24, 2025 to March 12, 2026, centered on the collapse of the TACTI-004 trial.ADRs fell to $0.48 from $2.76 on March 13, 2026, a one-day drop of 83% that erased $2.28 per share.The suit names CEO Marc Voigt, Chief Scientific Officer Frédéric Triebel, and Chief Medical Officer Stephan Winckels as individual defendants under Section 20 control-person claims.Plaintiffs allege the executives misled investors about trial progress while holding adverse non-public interim data, including through Sarbanes-Oxley certifications tied to SEC filings.A court deadline of July 6, 2026 has been set for investors seeking appointment as lead plaintiff.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL3s7WXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Immutep executives face securities class action after ADRs plunge 83% on trial collapse","news_tag":"executive,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631090631","title":"Immutep Receives Nasdaq Notice of Bid Price Deficiency","url":"https://stock-news.laohu8.com/highlight/detail?id=2631090631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631090631?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:00","pubTimestamp":1777550406,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nTUA5TB9FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631743315","title":"Immutep gets Nasdaq notice for breaching US$1 minimum bid price rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2631743315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631743315?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:39","pubTimestamp":1777513157,"startTime":"0","endTime":"0","summary":"Immutep received a Nasdaq notice of non-compliance with minimum bid price rule requiring at least US$ 1 per share.Nasdaq granted a 180-day compliance window expiring Oct. 26, 2026 to regain compliance.Compliance can be restored if ADS closing bid price reaches at least US$ 1 for 10 consecutive business days.Notice has no immediate impact on Nasdaq listing or trading of Immutep ADS.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLjS1mR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631015571","title":"BRIEF-Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631015571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631015571?lang=en_us&edition=fundamental","pubTime":"2026-04-30 09:33","pubTimestamp":1777512781,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Receives NASDAQ Notice Of Minimum Bid Price Non-ComplianceApril 30  - Immutep Ltd IMM.AX:RECEIVES NASDAQ NOTICE OF MINIMUM BID PRICE NON-COMPLIANCEREMAINS LISTED ON ASX; NASDAQ NOTICE DOES NOT AFFECT ASX TRADINGHAS 180 DAYS UNTIL OCTOBER 26, 2026 TO REGAIN NASDAQ COMPLIANCEFurther company coverage: IMM.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41C1U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631857337","title":"Immutep Ltd - Receives Nasdaq Notice of Minimum Bid Price Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2631857337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631857337?lang=en_us&edition=fundamental","pubTime":"2026-04-30 07:22","pubTimestamp":1777504933,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nFWN41C1U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":58,"code":"91000000","status":"200"}]}}